UCB stock
Price history
+29.35% over the period1 year: from €228.60 (November 17, 2025) to €295.70 (November 16, 2026), +29.35%.
Show chart data
Closing prices adjusted for splits: the last close of each month.
| Date | Close |
|---|---|
| November 16, 2026 | €295.70 |
| October 30, 2026 | €281.40 |
| September 30, 2026 | €205.10 |
| August 31, 2026 | €215.30 |
| July 31, 2026 | €222.90 |
| June 30, 2026 | €262.00 |
| May 29, 2026 | €251.70 |
| April 30, 2026 | €231.20 |
| March 31, 2026 | €258.50 |
| February 27, 2026 | €252.30 |
| January 30, 2026 | €255.40 |
| December 31, 2025 | €238.60 |
| November 28, 2025 | €240.50 |
| November 17, 2025 | €228.60 |
At a glance
The company
Biopharmaceutical company developing medicines for neurological and immunological diseases
Latest results
Quarter to June 30, 2026 · EPS €5.73 (estimate €5.04)
TickerLandia's take on UCB
- Pricier than usual relative to earnings: P/E on the latest fiscal year 37 vs a median of 22 over its last 10 fiscal years.
- Cheaper than similar companies: trailing 12-month P/E 26 vs 40 (−35%) in a group of 10.
- Strong point: Earnings stability (84/100 in its group). Weak point: Financial strength (34/100).
Analysis calculated by TickerLandia from financial statements and prices, with public rules. Not investment advice. How we analyse stocks
Where the price stands
−1.83% from the 52-week high
Analysts · 20 analysts
Average target€298.63+0.99% vs. price
Buy 15 · Hold 5 · Sell 0 · Buy
TickerLandia Fingerprint: UCB
Compared with similar companies: very high earnings stability, very strong momentum, and very high risk.
Financials and price compared with 61 companies in the biotechnology industry, worldwide. Momentum and risk compared with 1,160 European stocks.
Pricelow36
How much it costs relative to what it produces.
Metric Value Position in group Price/book 4.85 42 P/E (trailing 12 months) 26.2 32 Price/sales 6.63 34 Forward P/E 19.8 32 EV/EBITDA 18.9 38 Profitabilityhigh65
How much it earns on revenue and capital.
Metric Value Position in group Operating margin 29.5% 70 Net margin 25.7% 70 ROE 20.6% 70 Gross margin 76.2% 50 ROA 8.3% 68 Earnings stabilityvery high84
How steady its margins were over the last five annual reports.
Metric Value Position in group Margin variabilitycounts in reverse: lower means more earnings stability 6.1% 85 Loss-making yearscounts in reverse: lower means more earnings stability 0 of 5 annual reports 84 Growthaverage57
How fast revenue and earnings are growing.
Metric Value Position in group Revenue growth (year over year) +22.50% 53 Earnings growth (year over year) +134.80% 86 Average revenue growth (3 years) +12.43% 31 Financial strengthlow34
How well it would weather a hard period: debt, liquidity, interest.
Metric Value Position in group Net debt/EBITDAcounts in reverse: lower means more financial strength · more cash than debt −0.00 41 Interest coverage 13.9 53 Debt/equitycounts in reverse: lower means more financial strength 0.31 36 Current ratio 1.20 6 Dividendaverage51
How much it returns to shareholders, and for how long.
Metric Value Position in group Consecutive dividend years 27 years 87 Payout ratio 12.8% 31 Dividend yield 0.5% 36 Market momentumvery strong84
How the stock has moved compared with the market.
Metric Value Position in group 1-year return +33.08% 78 Distance from 200-day average +21.71% 91 Riskvery high81
How much the price swings.
Metric Value Position in group Volatility (60 days) 50.1% 92 Maximum drawdown (12 months) 30.7% 70
Position in the group from 0 to 100 (100 = highest value): it describes, it does not rate. Tap a row for the metrics. Calculated on November 16, 2026. An indicator calculated by TickerLandia from financial statements and market data. How it is calculated
Valuation
UCB is pricier than in the past and cheaper than similar companies
On the latest fiscal year's earnings (2025), UCB's P/E today is 36.8, above the median of its last 10 fiscal years (21.8; between 16.6 and 44.8 from 2016 to 2025). UCB's P/E (trailing 12 months): 26.2, −35% against the median of a group of 10 similar companies (40.4).
Compared with 10 similar companies
| Metric | UCB | Position in the group | Band |
|---|---|---|---|
| P/E (trailing 12 months) | 26.2 | Middle | |
| Forward P/E | 19.8 | Low | |
| Operating margin | 29.5% | Middle | |
| ROE | 20.6% | High | |
| Debt/equity | 0.31 | High |
P/E at fiscal year end; today on the latest fiscal year's earnings. Grey band: the middle half of the group; tick: the median; dot: UCB. All multiples and dividends
TickerLandia analysisHow it is calculated
The financials
The business in numbers
Revenue
€4.27B
Latest quarter · Q2 2026
Net income
€1.11B
Latest quarter · Q2 2026
Quarterly net margin
26.0%
Latest quarter · Q2 2026
Numbers and valuation
Full valuation- Market cap
- €56.53B
- P/E
- 26.2
- EPS
- €11.32
- Volume
- 170.43K
- Daily trading
- €85.75M
- Dividend yield
- 0.49%
- Last ex-dividend on May 4, 2026
How UCB is changing
All resultsRevenue grew 7.7% a year on average over the last 5 years
Operating margin rose from 11.0% to 23.0%
Profits turn into cash: free cash flow equal to 119% of net income
Returns
UCB returns with dividends
€1,000 invested in UCB 5 years ago, on November 16, 2021, would be worth €2,977 today with dividends reinvested: +197.66% in total, +24.38% per year. On price alone it would be €2,820 (+182.02%).
| Period | UCB | €1,000 becomes |
|---|---|---|
| 1 month | +44.53% | €1,445 |
| 6 months | +24.77% | €1,248 |
| Year to date | +23.93% | €1,239 |
| 1 year | +30.17% | €1,302 |
| 3 years | +348.61% | €4,486 |
| 5 years | +197.66% | €2,977 |
| 10 years | +414.54% | €5,145 |
From 1 year up with dividends reinvested, before taxes; under a year price only. Calculate your investment
The chart in detail
UCB: technical analysis
UCB shows no clear trend: the price and its 50- and 200-session averages are not aligned. The price is 1.0% below its all-time closing high (€298.80, November 9, 2026).
- Trend
- No clear trend
- RSI (14 sessions)
- 75
- Above 70: a strong rise in a short time
- vs 200-session average
- +21.31%
Active signals
RSI above 70: the stock has risen a lot in a short time.
since October 22, 2026
Support and resistance
Price areas where UCB has stopped several times in the last year. They describe the chart; they are not forecasts.
- No resistance above: the price is near the highs of the year
- Last price€295.70
- Support€276.95−6.34%2 touches, last on June 12, 2026
- Support€268.87−9.07%3 touches, last on July 1, 2026
- Support€250.77−15.20%3 touches, last on July 29, 2026
Volatility and risk
- Volatility (60 sessions, annualised)
- 50.0%
- Largest fall in the last year
- −30.66%
In session, November 16, 2026. Descriptive data calculated on daily prices: it describes the chart and is not investment advice. Beta and volatility describe the last year and can change a lot from one year to the next. How we calculate it
UCB: seasonality
Average monthly price change over 37 years
Over the last 37 years, the strongest month for UCB has been July: +2.86% on average, positive in 23 years out of 37. The weakest has been February: −0.48% on average, positive in 17 years out of 37. November, the current month, has been positive in 19 years out of 36 (+0.61% on average).
Show chart data
| Month | Average | Median | Positive years |
|---|---|---|---|
| January | +2.71% | +2.45% | 23 of 36 |
| February | −0.48% | −0.90% | 17 of 37 |
| March | −0.39% | −0.54% | 17 of 37 |
| April | +1.78% | +0.54% | 20 of 37 |
| May | +1.48% | −0.61% | 17 of 37 |
| June | +1.39% | −0.24% | 18 of 37 |
| July | +2.86% | +3.45% | 23 of 37 |
| August | +0.67% | +1.56% | 21 of 37 |
| September | +0.63% | +0.19% | 19 of 37 |
| October | +1.17% | +0.80% | 19 of 37 |
| November | +0.61% | +0.24% | 19 of 36 |
| December | +2.58% | +1.24% | 23 of 36 |
Price change only, dividends excluded. Past seasonality does not predict future moves.
The company
UCB and its competitors
Employing 9,000 people, UCB SA develops medicines for people with neurology and immunology conditions, serving patients worldwide. Epilepsy treatments such as Keppra and Vimpat sit alongside Neupro for Parkinson's disease, while Cimzia and Bimzelx address several inflammatory conditions, including plaque psoriasis and psoriatic arthritis. Evenity, for osteoporosis in postmenopausal women, and Fintepla, for Dravet and Lennox-Gastaut syndromes, add to the range, and the pipeline includes bepranemab for Alzheimer's disease and dapirolizumab pegol for systemic lupus erythematosus. The company also engages in contract manufacturing.
- Headquarters
- Brussels, Belgium
- Employees
- 9,000
- Founded
- 1925
- Chief executive
- Jean-Christophe Tellier
| Company | Market cap | Operating margin | P/E (trailing 12 months) | 6 months |
|---|---|---|---|---|
| UCBUCB | $62.48B | 29.5% | 26.2 | +24.77% |
| GenmabGMAB | $32.21B | 30.6% | 47.0 | +109.80% |
| Financière de TubizeTUB | $11.2B | -42,153.6% | 102.5 | +22.14% |
| ALK-AbellóALK.B | $8.14B | 26.9% | 40.7 | −1.11% |
| ABIVAXABVX | $7.65B | -6,270.4% | — | −21.10% |
| Bachem HoldingBANB | $7.43B | 21.8% | 41.9 | +5.24% |
Same industry or related industries, similar size. Compare UCB with its competitors · Full profile
